Abiogen Pharma Signed an Agreement With Lee's Pharma for License, Distribution and Supply Agreement to Market Neridronic Acid in China, Taiwan, Hong Kong and Macau

PISA, Italy and HONG KONG, May 26, 2014 /PRNewswire/ --

Abiogen Pharma S.p.A. of Pisa Italy and Lee's Pharm jointly announced the agreement for License, Distribution and Supply for marketing of Attila® (Neridronic Acid) throughout China, Hong Kong, Macau and Taiwan. Under the term of the agreement, Abiogen Pharma S.p.A. granted  Lee's Pharm an exclusive license and right for registering, importing, marketing, distributing and selling Attila® in the territory, for the two orphan/rare disease indications  Osteogenesis Imperfecta (OI) and Complex Regional Pain Syndrome (CRPS). Neridronate is the only therapeutic agent approved in the world for such orphan diseases: OI (1 in 10,000 in UE) and CRPS (3 in 10,000 in UE). Attila® is registered in Italy and used by patients in 32 European countries under the trade name of Nerixia®. Neridronate showed superior safety profile in long-term use and is highly tolerated by adults and pediatric population. It is the only bisphosphonate indicated for use in neonates and children. Dr. Massimo Di Martino, President & CEO of Abiogen Pharma said: "I am happy to see that Neridronate could cross political and geographic barriers to benefit the patients. Our partnership with Lee's Pharm will help patients in China and Taiwan to fight critical rare diseases for which there is no other treatment option available." Dr. Benjamin Li, Lee's Pharm Chief Executive Officer, said: "We're extremely pleased with our partnership with Abiogen Pharma, and excited about the opportunity to work on Neridronate in our territory. This is the fourth orphan drug we have licensed-in and it again demonstrates our commitment to rare diseases."

About Attila® (sodium neridronate) 

Attila® is an aminobisphosphonate developed and owned by Abiogen Pharma, Pisa. The Anti-resorptive activity leads to decrease the bone turnover, which is the basis for using this drug in Osteogenesis imperfecta. It is the only bisphosphonate approved for use in infants, children and adults. The product obtained first registration in Italy in 2002 as Nerixia®.

About Abiogen Pharma 

Abiogen Pharma, Pisa of Italy is a privately owned specialist pharmaceutical company focused on bone metabolism and some rare diseases.

For more information, please visit http://www.abiogen.it.

About Lee's Pharmaceutical 

Lee's Pharm is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry.

For more information, please visit http://www.leespharm.com.

SOURCE Abiogen Pharma